Economic advice, method- and data-based

We are a team of experts, researchers and practitioners with many years of economic experience in various industries. Our methods are data-based, incorporate the latest research findings and are field-tested. This enables us to create reliable analysis and solutions tailored to your requirements and the objectives of your company, public authority or association.

News

Epi­de­mio­lo­gy of Sick­le Cell Di­se­a­se in Switz­er­land

Sickle cell disease is a rare hereditary blood disorder, in which the red blood cells contain an altered form of haemoglobin (haemoglobin S), causing them to become sickle-shaped, thereby easily clump-ing together and clogging blood vessels. In this report, we make a rough estimation of the preva-lence (frequency of the disease: How many cases are there?) and incidence (new occurrences of the disease: How many cases are added annually?) of sickle cell disease for Switzerland. The existing data for Switzerland are of poor quality, which is why we transfer estimates for Germany to Switzer-land. It appears that there can be assumed to be between 200 and 700 existing cases in Switzerland (prevalence) as well as annually 8 to 16 births with sickle cell disease (incidence).

H2 Ba­ro­me­ter Switz­er­land, edi­ti­on 4, Oc­to­ber 2023

Compared to the previous year, the assessment of the investment climate in the Swiss hydrogen industry has deteriorated all along the value chain: three out of four respondents evaluate it negatively. Explanations can be found in the government conditions, which are consistently assessed as less good, but also in the persistently high electricity prices. Despite or precisely because of the uncertainties about the future role of hydrogen, Switzerland should not miss the opportunity to connect to the European Hydrogen Backbone (EHB) - the European hydrogen transport infrastructure. This requires swift and decisive action by the state to keep options open for the energy mix of the future. The activities of neighboring countries show that Europe is not waiting for Switzerland to build up its hydrogen supply. These topics are covered in the new H₂ Barometer, published by the Swiss Gas Industry Association in collaboration with E-Bridge Consulting and Polynomics. The Barometer is published twice a year and available in German and French. You can receive future issues by registering here: gazenergie.ch

Out­pa­ti­ent ca­re struc­tu­re for me­di­cal la­bo­ra­to­ry ana­ly­ses in Switz­er­land

The FOPH's transAL-2 project is currently revising the analysis list and its tariffs, i.e. the medical laboratory services that are reimbursed by the OKP. Polynomics has analysed outpatient laboratory care in Switzerland with health insurer data as part of transAL-2. The analyses show that the types of hospital laboratory defined in Article 54 KVV do not exist in reality. Overall, contract and hospital laboratories provided medical analyses worth around CHF 1.2 billion at the expense of the OKP in 2019. The heterogeneity between the service providers is very high. For example, the seven largest laboratory chains provided 80% of the gross services of the contract laboratories and the five university hospitals provided 40% of the gross outpatient services of the hospital laboratories. The range of services, measured by the number of different tests, also varies greatly. It can also be seen that the contract laboratories tend to be located in the large cities and regional centres, while the regional distribution of the hospital laboratories is more diverse.

Publications

Epidemiology of Sickle Cell Disease in Switzerland

Sickle cell disease is a rare hereditary blood disorder, in which the red blood cells contain an altered form of haemoglobin (haemoglobin S), causing them to become sickle-shaped, thereby easily clumping together and clogging blood vessels. In this report, we make a rough estimation of the prevalence (frequency of the disease: How many cases are there?) and incidence (new occurrences of the disease: How many cases are added annually?) of sickle cell disease for Switzerland. The existing data for Switzerland are of poor quality, which is why we transfer estimates for Germany to Switzerland. It appears that there can be assumed to be between 200 and 700 existing cases in Switzerland (prevalence) as well as annually 8 to 16 births with sickle cell disease (incidence).

Barometer Switzerland, edition 4, October 2023

Compared to the previous year, the assessment of the investment climate in the Swiss hydrogen industry has deteriorated all along the value chain: three out of four respondents evaluate it negatively. Explanations can be found in the government conditions, which are consistently assessed as less good, but also in the persistently high electricity prices.   Despite or precisely because of the uncertainties about the future role of hydrogen, Switzerland should not miss the opportunity to connect to the European Hydrogen Backbone (EHB) - the European hydrogen transport infrastructure. This requires swift and decisive action by the state to keep options open for the energy mix of the future. The activities of neighboring countries show that Europe is not waiting for Switzerland to build up its hydrogen supply.   These topics are covered in the new H₂ Barometer, published by the Swiss Gas Industry Association in collaboration with E-Bridge Consulting and Polynomics. The Barometer is published twice a year and available in German and French. You can receive future issues by registering here: https://gazenergie.ch/de/h2-barometer

Outpatient care structure for medical laboratory analyses in Switzerland

The FOPH's transAL-2 project is currently revising the analysis list and its tariffs, i.e. the medical laboratory services that are reimbursed by the OKP. Polynomics has analysed outpatient laboratory care in Switzerland with health insurer data as part of transAL-2. The analyses show that the types of hospital laboratory defined in Article 54 KVV do not exist in reality. Overall, contract and hospital laboratories provided medical analyses worth around CHF 1.2 billion at the expense of the OKP in 2019. The heterogeneity between the service providers is very high. For example, the seven largest laboratory chains provided 80% of the gross services of the contract laboratories and the five university hospitals provided 40% of the gross outpatient services of the hospital laboratories. The range of services, measured by the number of different tests, also varies greatly. It can also be seen that the contract laboratories tend to be located in the large cities and regional centres, while the regional distribution of the hospital laboratories is more diverse.